Skip to content
Review Open access

Efficacy, safety and outcome of selective IL-23 inhibitor risankizumab in induction and maintenance of CD and ulcerative colitis

Aug 2026 · Medicine · Vol 105 · 0 citations · 42 references
Medicine

TL;DR

RZB is an effective and well-tolerated treatment for moderate-to-severe CD and UC, showing strong clinical and endoscopic outcomes, but further research is needed to assess long-term efficacy and safety.

Abstract

Background: Crohn disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases characterized by immune dysregulation. Despite biologic advancements, many patients experience treatment failure. Risankizumab (RZB), a selective interleukin-23 inhibitor, has emerged as a promising therapy for moderate-to-severe inflammatory bowel diseases. This systematic review evaluates its efficacy, safety, and therapeutic outcomes. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic search of PubMed, Embase, Scopus, and ClinicalTrials.gov was conducted to identify studies published up to 2025. Eligible studies included randomized controlled trials, clinical trials, and retrospective observational studies evaluating RZB in adult patients with CD or UC. Primary outcomes included clinical remission, endoscopic response, hospitalization rates, and adverse events. Results: Seventeen studies involving 6602 patients (5627 with CD, 975 with UC) were analyzed. In CD, RZB demonstrated high clinical remission rates, endoscopic healing, and reduced hospitalizations, including in biologic-refractory patients. In UC, it showed significant remission rates and fewer UC-related hospitalizations. RZB was well tolerated, with mostly mild to moderate adverse events such as arthralgia, headache, and nasopharyngitis. Severe adverse events were rare. Conclusion: RZB is an effective and well-tolerated treatment for moderate-to-severe CD and UC, showing strong clinical and endoscopic outcomes. It offers a viable option for biologic-refractory patients, but further research is needed to assess long-term efficacy and safety.

Read PDF

Similar papers

Review Open access Sep 2026

NEW PERSPECTIVES IN THE TREATMENT OF ULCERATIVE COLITIS IN ADULTS - IL-23 INHIBITORS: EFFICACY AND SAFETY

Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent inflammation of the colon resulting from immune dysregulation. Despite the availability of multiple therapeutic options, a substantial proportion of patients fail to achieve sustained remission or develop loss of re...

Zuzanna Ostrowska, Z. Witkowska, Bartosz Rutka et al. · 0 citations
Open access Sep 2026

Towards Precision Medicine in Inflammatory Bowel Diseases: Pharmacogenetic Predictors of Ustekinumab Effectiveness and Persistence

IL12B rs6887695 emerged as a potential pharmacogenetic marker associated with favorable ustekinumab outcomes; however, this exploratory and hypothesis-generating finding requires external validation in larger, independent cohorts before clinical application.

Ylenia Marino, M. Rottura, Claudia Ligresti et al. · 0 citations
Review Open access Sep 2026

Safety and Efficacy of Anti-TL1A Monoclonal Antibodies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Background & Objective: Tumor necrosis factor-like ligand 1A (TL1A) has been associated with mucosal inflammation, fibrosis, and epithelial barrier dysfunction in inflammatory bowel disease (IBD). Monoclonal antibodies against TL1A have emerged as potential therapies for moderate-to-severe ulcerative colitis (UC) and C...

Hannan Adil, M. Adil, Samawia Kousar et al. · 0 citations
Review Open access Aug 2026

Targeted Therapies in Inflammatory Bowel Disease: Mechanisms, Comparative Evidence, and Clinical Translation

The current evidence supports mechanism-informed rather than biomarker-defined treatment selection, and the mechanistic rationale, comparative clinical evidence, and translational implications of approved and emerging targeted therapies for adult IBD are examined.

C. Pavel, A. Popa, M. Ilie et al. · 0 citations
Open access Nov 2026

Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis

BACKGROUND Many patients with Crohn’s disease (CD) remain uncontrolled despite multiple biologic therapies. Risankizumab, a selective interleukin-23p19 inhibitor, has shown efficacy in clinical trials, but real-world data in multirefractory CD are still scarce. AIM To evaluate the 12-month effectiveness and safety o...

A. Caballero-Mateos, T. Valdés-Delgado, R. Olmedo Martín et al. · 1 citation
Review Sep 2026

Vedolizumab trough concentrations and clinical and endoscopic outcomes in inflammatory bowel disease: a systematic review and meta-analysis.

BACKGROUND AND AIMS The role of therapeutic drug monitoring (TDM) in optimizing vedolizumab (VDZ) therapy for Crohn's disease (CD) and ulcerative colitis (UC) remains unclear. Prior evidence was limited by small sample size and heterogeneous endpoints. We synthesized the available evidence on the association of VDZ tro...

Mostafa A. Soliman, Alessandra Saraga, A. Gade et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.